OpenLobby.EU
Explore

Eli Lilly and Company

Lilly

Eli Lilly is a global biopharmaceutical company focused on innovative drug discovery.

Lobbying Activity

Meeting with Marta Temido (Member of the European Parliament)

13 Nov 2025 · Saúde

Meeting with Olivér Várhelyi (Commissioner) and

4 Nov 2025 · Competitiveness of the pharma industry

Meeting with Laszlo Kristoffy (Cabinet of Commissioner Olivér Várhelyi)

15 Oct 2025 · Pharmaceutical package

Meeting with Nina Carberry (Member of the European Parliament)

14 Oct 2025 · Alzheimers Research

Meeting with Victor Negrescu (Member of the European Parliament) and American Chamber of Commerce to the European Union and

8 Oct 2025 · AmCham EU Healthcare Committee Meeting

Meeting with Hildegard Bentele (Member of the European Parliament) and American Chamber of Commerce to the European Union and

8 Oct 2025 · Biotech

Meeting with Stine Bosse (Member of the European Parliament)

25 Sept 2025 · EU pharmaceutical policy

Eli Lilly Urges Integrated EU Strategy for Heart and Obesity

15 Sept 2025
Topic — The consultation seeks to establish a comprehensive EU cardiovascular health action plan.
Message — Eli Lilly seeks to integrate obesity management into standard cardiovascular healthcare. They request joint health checks and updated labels for weight management medicines. The group also proposes an EU-wide registry for tracking cardiometabolic health data.1234
Why — Updated labeling regulations would secure more favorable pricing and wider reimbursement for drugs.5
Read full response

Meeting with Pietro Fiocchi (Member of the European Parliament)

16 Jul 2025 · Tematiche Sanitarie

Meeting with Tomislav Sokol (Member of the European Parliament)

15 Jul 2025 · Health policy

Meeting with Tiemo Wölken (Member of the European Parliament, Rapporteur)

14 Jul 2025 · Pharma Package

Meeting with Aurelijus Veryga (Member of the European Parliament)

8 Jul 2025 · Improving Heart and Metabolic Health Across the EU

Meeting with Michael McGrath (Commissioner) and

27 Jun 2025 · Exchange of views on issues relating to competitiveness and corporate sustainability

Meeting with Olivér Várhelyi (Commissioner) and

17 Jun 2025 · EU health policy

Meeting with Ilhan Kyuchyuk (Member of the European Parliament)

14 May 2025 · Innovative Alzheimer's treatment in Europe

Meeting with Kristian Vigenin (Member of the European Parliament)

14 May 2025 · New healthcare and pharma initiatives

Meeting with Marco La Marca (Cabinet of Commissioner Dubravka Šuica) and Microsoft Corporation and

6 May 2025 · Demographic Policy

Meeting with Laszlo Andrejko (Cabinet of Commissioner Olivér Várhelyi)

30 Apr 2025 · EU health policy

Meeting with Marion Walsmann (Member of the European Parliament, Rapporteur)

2 Apr 2025 · Supplementary Certificates

Meeting with Tomislav Sokol (Member of the European Parliament)

6 Mar 2025 · Health policy

Meeting with Olivér Várhelyi (Commissioner) and

26 Feb 2025 · Healthcare, biotech and agri-food policies

Meeting with Rainer Becker (Director Health and Food Safety)

4 Feb 2025 · Exchange of views on the Clinical Trials Regulation (CTR), In-Vitro Diagnostic Regulation (IVDR) and their interface. Discussion on the clinical trial environment in Europe and globally.

Meeting with Eszter Lakos (Member of the European Parliament)

14 Jan 2025 · Clinical trials regulations

Meeting with András Tivadar Kulja (Member of the European Parliament)

11 Dec 2024 · European healthcare

Meeting with Ilia Lazarov (Member of the European Parliament)

5 Dec 2024 · Introductory meeting with representative

Meeting with Brando Benifei (Member of the European Parliament)

11 Nov 2024 · Priorities for the new mandate on health

Meeting with Margarita De La Pisa Carrión (Member of the European Parliament)

5 Nov 2024 · Pharma regulation

Meeting with András Tivadar Kulja (Member of the European Parliament) and Alzheimer Europe

5 Nov 2024 · Alzheimer disease

Meeting with Oliver Schenk (Member of the European Parliament) and Novartis International AG and

4 Nov 2024 · Pharmastandort Deutschland

Meeting with Laurent Castillo (Member of the European Parliament)

24 Oct 2024 · Obésité & Europe de la Santé

Meeting with Elena Nevado Del Campo (Member of the European Parliament)

24 Oct 2024 · Diabetes and Obesity care

Meeting with Vytenis Povilas Andriukaitis (Member of the European Parliament) and American Chamber of Commerce to the European Union

23 Oct 2024 · EU health policy

Meeting with Elena Nevado Del Campo (Member of the European Parliament)

16 Oct 2024 · Discussion on Alzheimer disease

Meeting with Tomislav Sokol (Member of the European Parliament) and European Federation of Associations of Health Product Manufacturers and Children's Tumor Foundation Europe

16 Oct 2024 · Health policy

Meeting with Peter Van Kemseke (Cabinet of President Ursula von der Leyen)

10 Oct 2024 · EB Summit

Meeting with João Cotrim De Figueiredo (Member of the European Parliament)

2 Oct 2024 · Government Affairs - Introductory meeting

Meeting with Kristian Vigenin (Member of the European Parliament)

2 Oct 2024 · Pharma legislation

Meeting with Radan Kanev (Member of the European Parliament)

23 Sept 2024 · Intellectual Property and EU Legislation

Meeting with Aldo Patriciello (Member of the European Parliament) and FuelsEurope and Acumen Public Affairs

18 Sept 2024 · first general meeting

Meeting with Michalis Hadjipantela (Member of the European Parliament) and Acumen Public Affairs

18 Sept 2024 · Early diagnosis of diabetes in Europe

Meeting with Ruggero Razza (Member of the European Parliament) and Acumen Public Affairs

17 Sept 2024 · Incontro conoscitivo e scambio di vedute sul mandato del Parlamento europeo

Meeting with Dimitris Tsiodras (Member of the European Parliament)

11 Sept 2024 · Meeting with the pharmaceutical sector

Meeting with András Tivadar Kulja (Member of the European Parliament)

11 Sept 2024 · Innovation and Health policy

Meeting with Eszter Lakos (Member of the European Parliament)

11 Sept 2024 · Public health

Meeting with Kathleen Funchion (Member of the European Parliament) and Cook Medical EMEA Group Limited

10 Sept 2024 · Introductory Meeting

Meeting with Isabella Tovaglieri (Member of the European Parliament)

10 Sept 2024 · European regulation in pharmaceutical sector

Meeting with Pietro Fiocchi (Member of the European Parliament)

10 Sept 2024 · Pharmaceutical

Meeting with Regina Doherty (Member of the European Parliament)

10 Sept 2024 · Innovation and competitiveness

Meeting with Stine Bosse (Member of the European Parliament)

9 Sept 2024 · European health policy

Meeting with Sara Cerdas (Member of the European Parliament)

19 Mar 2024 · Reunião Eli Lilly

Meeting with Beatrice Covassi (Member of the European Parliament)

6 Mar 2024 · Health

Meeting with Maria Veronica Rossi (Member of the European Parliament)

20 Feb 2024 · Pharmaceutical Strategy

Meeting with Brando Benifei (Member of the European Parliament)

20 Feb 2024 · Exchange of views on the Pharmaceutical Strategy for Europe

Meeting with Seán Kelly (Member of the European Parliament)

20 Feb 2024 · Informal Coffee meeting

Meeting with Laura Ballarín Cereza (Member of the European Parliament, Shadow rapporteur for opinion) and American Chamber of Commerce to the European Union and

23 Jan 2024 · Pharmaceutical Package (Regulation)

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur) and European Federation of Pharmaceutical Industries and Associations and

12 Dec 2023 · Directive on Medicinal products for human use

Meeting with Edina Tóth (Member of the European Parliament) and Vulcan Consulting Limited

15 Nov 2023 · Upcoming topics in ENVI Committee

Meeting with Stelios Kympouropoulos (Member of the European Parliament)

8 Nov 2023 · discussion on the General Pharmaceutical Package revision

Eli Lilly opposes EU plan to reduce drug patent protections

7 Nov 2023
Topic — EU regulation reforming pharmaceutical authorisation procedures and intellectual property incentives.
Message — Lilly requests greater regulatory data protection instead of reductions and opposes linking intellectual property to EU-wide market access. They advocate against expanding exemptions to pricing and reimbursement activities during patent terms. They support streamlined approval timelines and risk-based shortage prevention focused on critical medicines only.12345
Why — This would maintain patent protections supporting high-risk research investments in difficult diseases like Alzheimers.67
Impact — Generic manufacturers lose earlier opportunities to prepare market entry and price negotiations.8
Read full response

Eli Lilly opposes cuts to drug data protection periods

7 Nov 2023
Topic — EU revision of pharmaceutical legislation to improve access and foster innovation.
Message — Lilly requests maintaining strong Regulatory Data Protection without conditions linking IP to access in all EU27. They argue the proposed RDP reduction and conditionality system is unpredictable and undermines European competitiveness. They advocate for greater RDP to drive innovation into difficult diseases like Alzheimer's.123
Why — This would preserve IP incentives needed to justify high-risk investment in slow-progressing diseases.4
Impact — Generic and biosimilar manufacturers face continued delays in bringing affordable alternatives to market.5
Read full response

Meeting with Henna Virkkunen (Member of the European Parliament, Rapporteur for opinion) and Kangaroo Group

18 Oct 2023 · Medicinal products for human use

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur)

18 Oct 2023 · Directive on Medicinal products for human use

Meeting with Tiemo Wölken (Member of the European Parliament, Rapporteur) and European Federation of Pharmaceutical Industries and Associations and

7 Sept 2023 · Revision of the Pharmaceutical Legislation (staff level)

Meeting with Karsten Lucke (Member of the European Parliament, Rapporteur for opinion)

4 Jul 2023 · NCDs / Biotechnologie Investment

Meeting with Nicolás González Casares (Member of the European Parliament, Shadow rapporteur) and MEDICINES FOR EUROPE and

7 Jun 2023 · Medicines

Meeting with Nicola Beer (Member of the European Parliament)

26 May 2023 · Exhange of views

Eli Lilly Urges Shared Responsibility for Wastewater Costs

14 Mar 2023
Topic — The EU is revising rules to protect the environment from wastewater micropollutants.
Message — Lilly requests financial responsibility be shared among all sectors and product users. They also demand a mechanism to cap the scheme's cost and scope. The company argues that current data on pharmaceutical pollution is significantly flawed.123
Why — A cost cap would reduce financial uncertainty and lower compliance expenses.4
Impact — Other industrial sectors and the public would face increased treatment costs.5
Read full response

Meeting with Kevin Keary (Cabinet of Executive Vice-President Valdis Dombrovskis) and Novartis International AG and EuropaBio

6 Mar 2023 · Pharma package

Meeting with István Ujhelyi (Member of the European Parliament)

2 Mar 2023 · Diabetes

Meeting with István Ujhelyi (Member of the European Parliament) and Novartis International AG

1 Mar 2023 · Cardiovascular Health

Meeting with Susana Solís Pérez (Member of the European Parliament)

1 Mar 2023 · Diabetes and obesity in Europe

Meeting with Patricia Reilly (Cabinet of Commissioner Mairead Mcguinness) and European Federation of Pharmaceutical Industries and Associations and

10 Feb 2023 · Discussion of upcoming pharmaceutical package; value of predictability (IP), EU pharmaceutical product approval process, competitiveness, unmet medical needs.

Meeting with Franc Bogovič (Member of the European Parliament) and International Diabetes Federation European Region

12 Jan 2023 · Diabetes in the EU

Meeting with István Ujhelyi (Member of the European Parliament)

11 Jan 2023 · Diabetes and CVD

Meeting with Caroline Boeshertz (Cabinet of Executive Vice-President Valdis Dombrovskis)

7 Sept 2022 · Extension of the so-called ‘TRIPS waiver’ mechanism to therapeutics & diagnostics

Meeting with Nicola Danti (Member of the European Parliament)

31 May 2022 · Strategia industriale e farmaceutica

Meeting with Sara Cerdas (Member of the European Parliament)

20 May 2022 · Intelectual Property and Health Literacy

Meeting with Maria da Graça Carvalho (Member of the European Parliament)

18 May 2022 · Pharma strategy - industrial policy and innovation - shortages in supply chains of medicines

Meeting with Cristina Rueda Catry (Cabinet of Executive Vice-President Valdis Dombrovskis), Michael Hager (Cabinet of Executive Vice-President Valdis Dombrovskis)

22 Jun 2021 · Current trade policy issues EU-US trade relations

Response to Evaluation and revision of the general pharmaceutical legislation

26 Apr 2021

Eli Lilly & Company (Lilly) wishes to offer this solution-oriented reply for improving the EU medicines ecosystem, making life better for patients, and facilitating the EU’s leadership in life sciences. Future-proofed system Policies that enable adaptability and adequate resourcing will ensure that the EU regulatory system is efficient, effective, and competitive. Given the speed of drug and digital innovations, we believe that the EU regulatory system should better leverage simplifications, EU network’s vast expertise, and new flexibilities. Such modernisation requires proactive policies, advanced capabilities, and updated infrastructure to enable cutting-edge approaches such as innovative clinical trial designs, real-time regulatory reviews, real world data generation, e-labeling and cloud-based submissions. While non-legislative policies can enable faster regulatory actions today, the current EU regulatory framework is often considered as fragmented, multi-layered, and complex in comparison with other countries. This is illustrated in Annex Visual A and Visual B. We consider that streamlining this process incl. considering transitioning some capabilities to the EMA would offer a future-proofed and more agile system (e.g., Visual C). Competitive timelines We concur that EU’s regulatory review timelines could be swifter: in 2019, it took a median of 423 days for the EMA to approve a new active substance versus 243 days in the USA (Visual D). Along with simplifying the approval process, increasing the use of accelerated assessments, and shortening procedures (e.g., moving from 67 days to 7 days for final decision) would help meet this objective (Visual C). Expedited regulatory tools are key to an agile system and although some are available in the EU, their use is limited in comparison to those offered in other countries. As such, the impact of PRIME could be amplified if it (and/or similar approaches) were accessible for any product, indication, and company from early in development. Also, we believe that timelier regulatory dialogue would offer better integration of the EU scientific, clinical, and regulatory expertise into a medicine’s global development plan. Resilient supply chains Europe’s overall support for open trade helps maintain flexibility in global supply chains of medicines and their raw materials. This protects against shortages, with geographic diversity enabling access to the resources needed, and adjustments if necessary, to respond to operational disruptions and demand changes in both volume and location. Policies that mandate wholesale changes to global supply chains, e.g., location, sourcing or inventory, could distort the security and reliability of the supply. Supply chain robustness and resilience can be protected through policies that strengthen the R&D and manufacturing base, including ensuring a vibrant talent pool in STEM, complementary technical partners (SMEs, universities, etc.), strong and predictable IP protection, along with rapidly responding regulatory pathways. These help create a rich life sciences community and enable Europe to be a location of choice for pharmaceutical investment and operations. IP incentives IP and incentives play a vital role to encourage the development of new medicines for patients and R&D investment into Europe. The different incentives complement each other and are necessary. They work across potential differentiated opportunities for new innovative medicines that benefit patients by addressing unmet medical needs (UMNs) in all areas, including medicines for rare diseases and children. There are still many UMNs of all types that need to be addressed. We believe that predictability and certainty of incentives are key at the required point of investment. Additional novel incentives for UMN must also take this into account.
Read full response

Meeting with Barry Andrews (Member of the European Parliament)

20 Apr 2021 · Trade

Eli Lilly urges EU to protect patents and speed approvals

1 Jul 2020
Topic — The EU is consulting on a strategy for affordable medicines and supply chain security.
Message — The company calls for faster drug approvals and stronger intellectual property protections for innovative medicines. They suggest that regulatory flexibilities used during the pandemic should become permanent best practices. Eli Lilly also advocates for diverse global supply chains to ensure medicine manufacturing remains stable.123
Why — Stronger patent protections would ensure stable returns on investment for high-risk pharmaceutical development.4
Impact — Public health systems and patients lose the cost savings provided by cheaper generic medicines.5
Read full response

Meeting with Stella Kyriakides (Commissioner) and

5 Feb 2020 · Discussion on Cancer and Europe's Beating Cancer Plan

Meeting with Manuel Mateo Goyet (Cabinet of Commissioner Mariya Gabriel)

6 Sept 2018 · eHealth

Meeting with Maria Asenius (Cabinet of Vice-President Cecilia Malmström)

6 Sept 2018 · Current EU-US Trade relations; China; intellectual property rights

Meeting with Jyrki Katainen (Vice-President)

6 Sept 2018 · Intellectual property incentives framework in the EU, investment and innovation

Meeting with Vytenis Andriukaitis (Commissioner) and

29 Nov 2017 · Pharmaceutical incentives, antimicrobial resistance

Response to REACH Regulation - Annex XIV

13 Oct 2016

We welcome this opportunity and refer to 4-(1,1,3,3-Tetramethylbutyl)phenol , ethoxylated (Triton X-100). Pathogen safety is of upmost importance for biopharmaceuticals. Triton X-100 (T X-100) is the ‘gold standard’ pathogen inactivation method, referenced in WHO and EMA guidance as a viral inactivation (VI) agent. For 30+ years it has been robust and effective for VI, and is widely used in biologics that potentially treat millions of EU patients with conditions like Alzheimer’s, cancer and diabetes. Its continued use is essential for patient safety and to safeguard against emerging viruses. The current REACH Authorisation process is uncertain and risks putting patients’ health at risk. The original T X-100 proposal was missed by many for technical reasons. T X-100 is the only substance in this proposal which hasn’t been the object of a call for socio-economic information nor a RMOA by the Commission. The Commission’s calls for ECHA’s 6th and 7th recommendations indicated that information gathered aims to inform decision-making by the Commission and the REACH Committee. The absence of socio-economic data gathering to feed into an impact assessment, and the absence of consultation of stakeholders on T X-100, goes against the Commission’s Better Regulation guidelines. Today it is disproportionate to place T X-100 on Annex XIV for the life sciences, with the uncertainty it creates for security of supply of life enhancing medicines in human health/veterinary medicines. It also creates regulatory uncertainty for Lilly manufacturing. As with plasma derived products, VI is a critical step in the manufacturing process in mammalian culture systems. Alternative VI processes are unlikely to be validated and approved by regulatory agencies for existing commercialised medicines in time and the industry could have to seek supply from non-EU countries, like Switzerland, USA and the Far East. Even with Authorisation, the current periods granted (12 years max) does not address the long timelines that are required to bring our medicines to patients. Biopharma is <10% of 4-tert-OPnEO use, so an early loss of supply could also have an impact on public health. Global manufacturing location assessments are made today for medicines that are up to a decade from commercialisation, in early development. Lilly’s EU manufacturing locations in Ireland, Italy, France and Spain require a stable and predictable regulatory environment in order to make sourcing decisions for its medicines. REACH currently doesn’t provide this certainty. If T X-100 is banned in the EU then any potential new VI methods will have to be assessed and approved by the EMA. If a new VI manufacturing process is found and implemented at EU manufacturing facilities, a key step in the medicinal approval process could require additional animal testing and clinical trials and would add years of delay in new medicines reaching patients; with potential supply outages for current medicines. The alternative for multinational manufacturers is to utilise capacity available outside the EU and import the finished medicine. This is not desirable and goes against the Commission’s jobs and growth plan. A recent CRA report on T X-100 shows c.4,000 EU jobs supporting biopharmaceutical manufacturing are at risk. This could equate to a cost of €3.5 billion. CRA highlights the difficulty changing manufacturing location for marketed products and that revalidating the manufacturing process would add €20m+ cost per product. The EU is putting €billions in exports, many high value jobs and a global life science competitive advantage at risk. This risk cannot be properly considered without an accompanying Commission impact assessment. We call on the Commission to now do a benefit/risk management assessment on T X-100 use in relation to biopharmaceuticals and public health. We support the objectives of REACH and see the REACH Review as the way to make the process fit for purpose for life sciences.
Read full response

Meeting with Hilde Hardeman (Cabinet of Vice-President Jyrki Katainen), Marika Lautso-Mousnier (Cabinet of Vice-President Jyrki Katainen)

15 Jun 2016 · REACH

Meeting with Dermot Ryan (Cabinet of Commissioner Phil Hogan)

15 Jun 2016 · Interservice consultation on a substance used for disinfection in pharma processes called Triton X100

Meeting with Dermot Ryan (Cabinet of Commissioner Phil Hogan)

9 Mar 2016 · Lilly /Elanco footprint and vision / mission / Hunger / Feeding the world/ How it fits with EU exporting its agriculture

Meeting with Bernardus Smulders (Cabinet of First Vice-President Frans Timmermans) and DIGITALEUROPE and

14 Jan 2016 · AECA Round-Table on “Dealing with Regulatory Burden

Meeting with Marco Valletta (Cabinet of Commissioner Vytenis Andriukaitis), Marco Valletta (Cabinet of Commissioner Vytenis Andriukaitis)

3 Mar 2015 · Animal Health and Welfare, Food Security

Meeting with Annika Nowak (Cabinet of Commissioner Vytenis Andriukaitis)

6 Feb 2015 · Access to innovative medicine

Meeting with Rolf Carsten Bermig (Cabinet of Commissioner Elżbieta Bieńkowska)

21 Jan 2015 · Intro meeting

Meeting with Dermot Ryan (Cabinet of Commissioner Phil Hogan)

3 Dec 2014 · Sustainable agriculture contributing to economic growth

Meeting with Heidi Jern (Cabinet of Vice-President Jyrki Katainen)

2 Dec 2014 · Life sciences contribution to growth and jobs